Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
| Company Name | Founded | Funding Stage | Amount | City |
|---|---|---|---|---|
| Dianthus Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Waltham |
| Angitia Biopharmaceuticals | 2026 | Series D | Undisclosed | Westlake Village |
| Apeiron labs | 2026 | Series A | Undisclosed | Cambridge |
| Arcutis Biotherapeutics | 2024 | Post-IPO Equity | Undisclosed | Westlake Village |
| COMPASS Pathways | 2026 | Post-IPO Equity | Undisclosed | Altrincham |
| Zura Bio | 2026 | Post-IPO Equity | Undisclosed | Henderson |
| Bicara Therapeutics | 2026 | Post-IPO Equity | Undisclosed | Cambridge |
| Tyra Biosciences | 2024 | Post-IPO Equity | Undisclosed | Carlsbad |
| MMI | 2024 | Series C | Undisclosed | Pisa |
| Synthego | 2022 | Series E | Undisclosed | Redwood City |
| # | Company | Stage | Amount | Location |
|---|---|---|---|---|
| 76 | Dianthus Therapeutics | Post-IPO Equity | Undisclosed | Waltham, United States |
| 77 | Angitia Biopharmaceuticals | Series D | Undisclosed | Westlake Village, United States |
| 78 | Apeiron labs | Series A | Undisclosed | Cambridge, United States |
| 79 | Arcutis Biotherapeutics | Post-IPO Equity | Undisclosed | Westlake Village, United States |
| 80 | COMPASS Pathways | Post-IPO Equity | Undisclosed | Altrincham, United Kingdom |
| 81 | Zura Bio | Post-IPO Equity | Undisclosed | Henderson, United States |
| 82 | Bicara Therapeutics | Post-IPO Equity | Undisclosed | Cambridge, United States |
| 83 | Tyra Biosciences | Post-IPO Equity | Undisclosed | Carlsbad, United States |
| 84 | MMI | Series C | Undisclosed | Pisa, Italy |
| 85 | Synthego | Series E | Undisclosed | Redwood City, United States |
Dianthus Therapeutics is a biotech company developing new treatments for serious autoimmune diseases using a more targeted approach.
Angitia Biopharmaceuticals develops biologic therapies for musculoskeletal diseases.
Apeiron labs mission is to provide data from the upper of the ocean.
Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing medical dermatology for unmet needs.
Compass Pathways is a mental health care company that focuses on developing therapies for treatment-resistant depression.
Zura Bio is a clinical-stage, multi-asset biotechnology company.
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Tyra Biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.
MMI is focused on advancing robotic technology for soft tissue open surgery with the world's smallest wristed instruments.
Synthego is a genome engineering company that enables access to CRISPR to accelerate life science research and development.
Avilar Therapeutics is a biopharmaceutical company focusing on extracellular protein degradation.
Immunic is a biopharmaceutical company that develops a pipeline of selective oral immunology therapies.
Evommune is a biotechnology company that develops therapeutics that halt progressive disease and address their symptoms.
ILiAD is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis.
Galecto is a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer.
Hemab is a clinical-stage biotech company that develops prophylactic biologic therapies for underserved bleeding and thrombotic.
VitriVax is a formulation technology company that engineers solutions to maximize the accessibility and utility of human vaccines.
Adcytherix is a biopharmaceutical firm that specializes in the development of new antibody drug conjugates (ADC).
Indapta Therapeutics is a privately held biotechnology company.
Ansa Biotechnologies develops a novel DNA synthesis technology based on enzymes.
Star Therapeutics mission is to develop therapies for as many diseases as possible for millions of patients.
Sparrow Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for disorders of corticosteroid excess.
Delix Therapeutics focuses on harnessing the power of psychoplastogens novel neuroplasticity-promoting therapeutic.
Alchemab Therapeutics is developing protective antibodies designed to keep people free of hard-to-treat diseases.
Gameto is a biotechnology company developing therapeutics of the female reproductive system using cell engineering.
RA Capital Management has invested in 369 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
RA Capital Management's top investment sectors include Biotechnology, Life Science, Medical, Health Care, Biopharma. The firm invests across 23 different industry categories.
Among tracked funding rounds, Hemab received $157.0M in a Series C round. RA Capital Management's total known invested capital is $19.0B.
RA Capital Management's average investment size is $91.5M across its portfolio of 369 companies.
Recent RA Capital Management portfolio additions include Dianthus Therapeutics, Angitia Biopharmaceuticals, Apeiron labs, Arcutis Biotherapeutics, COMPASS Pathways. These companies were founded in 2020 or later.
Discover portfolio companies of other leading venture capital firms and investors.
View All Investors